Pramod Chauhan¹, Pratima Katiyar²*, Kalpana Kushwaha², Shivam Kumar Verma¹, Amana Parveen¹ and Raghvendra Kumar Yadav¹

¹Research Scholar, School of Pharmaceutical Sciences, CSJM University, Kanpur, U.P. India
²Assistant Professor, School of Pharmaceutical Sciences, CSJM University, Kanpur, U.P. India

*Corresponding Author: Pratima Katiyar, Assistant Professor, School of Pharmaceutical Sciences, CSJM University, Kanpur, U.P. India.

Received: October 14, 2021; Published: December 16, 2021

Abstract

Background: Millions of people in the world have been infected by respiratory viral infections (RVIs) especially upper respiratory infections such as pneumonia and deeper pulmonary infections. About 200 recognized respiratory viruses exist on the planet. They are broadly classified into a family of DNA viruses (Adenoviridae) and RNA viruses (Orthomyxoviridae, Paramyxoviridae, Picornaviridae, and Coronaviride). Among them, SARS-CoV-2 develops a disease named COVID-19. A big cause of the pandemic situation since 2019 and have a considerable impact on human life. Therefore, the prevention and control of SARS Co-V2 are major aims for researchers.

Main Body: The lack of effective vaccination against acute respiratory syndrome coronavirus-2 [SARS-CoV-2] infection has prompted increased efforts in direction of new medicines search. The repurposing of existing drugs has brought great hope for the treatment of pandemic covid-19 such as Ivermectin, an FDA-approved broad-spectrum antiparasitic recently, demonstrated significant antiviral activity in vitro against SARS-CoV-2. Adamantane derivatives have been also reported as antiviral drugs for respiratory viral infections. These drugs are reused in SARS CoV-2 treatment in the early stages for prophylactic purposes. Various stages are involved in virus propagation in a host cell, termed as “virus life cycle”. So, all stages in the virus life cycle are imminent targets for the discovery of new antiviral entities.

Conclusion: This review paper summarized all aspects of medicinal approaches and biological approaches to control and management of covid infection.

Keywords: Respiratory Viral Infections; SARS Co-v-2; Respiratory Syndrome; Adamantine; Antiviral Drugs; Virus Life Cycle; Vaccine

References

1. Andersen Paul. “Pathogenesis of lower respiratory tract infections due to Chlamydia, Mycoplasma, Legionella and viruses”. Thorax4 (1998): 302-307.
2. Jebril Nadia. “World Health Organization declared a pandemic public health menace: a systematic review of the coronavirus disease 2019 “COVID-19”” (2020).
3. Santacroce Luigi., et al. “The human coronaviruses (HCoVs) and the molecular mechanisms of SARS-CoV-2 infection”. Journal of Molecular Medicine1 (2021): 93-106.
4. Arefi Maryam Feiz and Mohsen Poursadeqiyan. “A review of studies on the epidemic crisis of COVID-19 disease with a preventive approach”. WorkPreprint (2020): 1-13.
5. Holmes Emily A., et al. “Multidisciplinary research priorities for the COVID-19 pandemic: a call for action for mental health science”. The Lancet Psychiatry6 (2020): 547-560.
6. Banerjee Anwesha., et al. “Herpes simplex virus: the hostile guest that takes over your home”. Frontiers in Microbiology11 (2020): 733.
7. Baggen Jim., et al. “The life cycle of non-polio enteroviruses and how to target it”. Nature Reviews Microbiology6 (2018): 368-381.
8. Kelleni Mina T. “Nitazoxanide/azithromycin combination for COVID-19: A suggested new protocol for early management”. Pharmacological Research157 (2020): 104874.
9. Ryu Wang-Shick. “Virus life cycle”. Molecular Virology of Human Pathogenic Viruses (2017): 31.
10. Vyas SP and V Sihorkar. “Endogenous carriers and ligands in non-immunogenic site-specific drug delivery”. Advanced Drug Delivery Reviews2-3 (2000): 101-164.
11. Patel Leena N., et al. “Cell penetrating peptides: intracellular pathways and pharmaceutical perspectives”. Pharmaceutical Research11 (2007): 1977-1992.
12. Whittaker Gary R., et al. “Viral entry into the nucleus”. Annual Review of Cell and Developmental Biology1 (2000): 627-651.
13. Kuznetsov Yurii G and Alexander McPherson. “Atomic force microscopy in imaging of viruses and virus-infected cells”. Microbiology and Molecular Biology Reviews2 (2011): 268-285.
14. Morens David M and Anthony S Fauci. “Emerging pandemic diseases: how we got to COVID-19”. Cell5 (2020): 1077-1092.
15. Eccleston-Turner M and McArdle S. “Accountability, international law, and the World Health Organization; A need for reform?”. Global Health1 (2017): 27-39.
16. Boldogh I., et al. “Persistent viral infections”. Medical Microbiology. 4^th edition (1996).
17. Roser Max., et al. “Coronavirus disease (COVID-19)-Statistics and research”. Our World in data 4 (2020).
18. Yaqoob S., et al. “An overview of novel coronavirus sars-cov-2 spanning around the past, present, and future perspectives”. Journal of Pure Applied Microbiology1 (2020): 775-788.
19. Zhou Yadi., et al. “Artificial intelligence in COVID-19 drug repurposing”. The Lancet Digital Health12 (2020):e667-e676.
20. Yavuz Serap and Serhat Ünal. “Antiviral treatment of COVID-19”. Turkish Journal of Medical SciencesSI-1 (2020): 611-619.
21. Gordon Calvin J., et al. “Remdesivir is a direct-acting antiviral that inhibits RNA-dependent RNA polymerase from severe acute respiratory syndrome coronavirus 2 with high potency”. Journal of Biological Chemistry20 (2020): 6785-6797.
22. Siegel Dustin., et al. “Discovery and synthesis of a phosphoramidate prodrug of a pyrrolo [2, 1-f] [triazin-4-amino] adenine C-nucleoside (GS-5734) for the treatment of Ebola and emerging viruses” (2017): 1648-1661.
23. Sheahan Timothy P., et al. “Broad-spectrum antiviral GS-5734 inhibits both epidemic and zoonotic coronaviruses”. Science Translational Medicine396 (2017).
24. Chu CM., et al. “Role of lopinavir/ritonavir in the treatment of SARS: initial virological and clinical findings”. Thorax3 (2004): 252-256.
25. Stockman Lauren J., et al. “SARS: systematic review of treatment effects”. PLoS Medicine9 (2006): e343.
26. Srivatsan Padmanabhan M. “Potential dual therapeutic approach against SARS-CoV-2/COVID-19 with Nitazoxanide and Hydroxychloroquine” (2020).
27. Wanka Lukas Khalid Iqbal and Peter R Schreiner. “The lipophilic bullet hits the targets: medicinal chemistry of adamantane derivatives”. Chemical Reviews5 (2013): 3516-3604.
28. Popescu Razvan Andrei., et al. “Supportive Care: Low Cost, High Value”. American Society of Clinical Oncology Educational Book41 (2021): 240-250.
29. Devaux Christian A., et al. “New insights on the antiviral effects of chloroquine against coronavirus: what to expect for COVID-19?”. International Journal of Antimicrobial Agents5 (2020): 105938.
30. Pandey Abhjieet., et al. “Potential therapeutic targets for combating SARS-CoV-2: Drug repurposing, clinical trials and recent advancements”. Life Sciences256 (2020): 117883.
31. Sheahan Timothy P., et al. “Broad-spectrum antiviral GS-5734 inhibits both epidemic and zoonotic coronaviruses”. Science Translational Medicine396 (2017).
32. Dixit Subhal B., et al. “Current approaches to COVID-19: therapy and prevention”. Indian Journal of Critical Care Medicine: Peer-Reviewed, Official Publication of Indian Society of Critical Care Medicine9 (2020): 838.
33. Rossignol Jean-François. “Nitazoxanide, a new drug candidate for the treatment of Middle East respiratory syndrome coronavirus”. Journal of Infection and Public Health3 (2016): 227-230.
34. Kelleni Mina T. “Nitazoxanide/azithromycin combination for COVID-19: A suggested new protocol for early management”. Pharmacological Research157 (2020): 104874.
35. Srivatsan Padmanabhan M. “Potential dual therapeutic approach against SARS-CoV-2/COVID-19 with Nitazoxanide and Hydroxychloroquine” (2020).
36. Bloch Evan M., et al. “Deployment of convalescent plasma for the prevention and treatment of COVID-19”. The Journal of Clinical Investigation6 (2020): 2757-2765.
37. Khaire Niranjan Shiwaji., et al. “Use of convalescent plasma for COVID-19 in India: A review and practical guidelines”. The Indian Journal of Medical Research1-2 (2021): 64.
38. Martins Filipe., et al. “Adverse effects of immune-checkpoint inhibitors: epidemiology, management and surveillance”. Nature Reviews Clinical Oncology9 (2019): 563-580.
39. Iacob Simona and Diana Gabriela Iacob. “SARS-coV-2 treatment approaches: numerous options, no certainty for a versatile virus”. Frontiers in Pharmacology11 (2020): 1224.
40. Gouglas Dimitrios., et al. “Estimating the cost of vaccine development against epidemic infectious diseases: a cost minimisation study”. The Lancet Global Health12 (2018): e1386-e1396.
41. Jackson Lisa A., et al. “An mRNA vaccine against SARS-CoV-2-preliminary report”. New England Journal of Medicine20 (2020): 1920-1931.
42. Flanagan Katie L., et al. “Progress and pitfalls in the quest for effective SARS-CoV-2 (COVID-19) vaccines”. Frontiers in Immunology11 (2020): 2410.
43. Silveira Marcelle Moura., et al. “DNA vaccines against COVID-19: Perspectives and challenges”. Life Sciences (2020): 118919.
44. Jiang Shibo. “Don't rush to deploy COVID-19 vaccines and drugs without sufficient safety guarantees”. Nature7798 (2020): 321-322.
45. Shen Chenguang., et al. “Treatment of 5 critically ill patients with COVID-19 with convalescent plasma”. JAMA16 (2020): 1582-1589.
46. Fan Linzi., et al. “COVID-19 drug treatment in China”. Current Pharmacology Reports4 (2020): 146-154.
47. Galeotti Caroline., et al. “Sustained remission of multicentric Castleman disease in children treated with tocilizumab, an anti-interleukin-6 receptor antibody”. Molecular Cancer Therapeutics8 (2012): 1623-1626.
48. Zhou Fei., et al. “Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study”. The Lancet10229 (2020): 1054-1062.
49. Price Christina C., et al. “Tocilizumab treatment for cytokine release syndrome in hospitalized patients with coronavirus disease 2019: survival and clinical outcomes”. Chest4 (2020): 1397-1408.
50. Pandya SN. “A Textbook of Medicinal Chemistry (Synthetic and Biochemical Approach)”. SG Publisher, Varanasi1 (2001): 107-109.

Citation

Citation: Pratima Katiyar., et al. “A Comprehensive Review: Prevention and Control of SARS Co-V-2". Acta Scientific Pharmaceutical Sciences 6.1 (2022): 67-75.

Copyright

Copyright: © 2022 Pratima Katiyar., et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.